Introduction
The number of patients suffering from end-stage renal disease has more than doubled over the past ten years. In order to stop this progression, risk factors and early stages of chronic kidney disease need to be evaluated (7) . Atherosclerosis is associated with renal dysfunction but the presence of lesions represents an advanced stage of the atherosclerotic process. Renal functional abnormalities, preceding the onset of ischemic nephropathy, may exist at early stages of atherogenesis (2, 7) . An early endothelial dysfunction is observed not only in atherosclerosis but also in hypertension, hypercholesterolemia and diabetes (15, 33) .
Vasoconstrictors can be responsible for the altered vascular responsiveness and activators of TP-receptors (receptors for thromboxane A 2 -TXA 2 ) are frequently involved (5, 43) .
Treatment of atherosclerotic patients with a single dose of the TP-receptor antagonist Triplion ® (S 18886) restores altered endothelium-dependent vasodilatation (3) . Similarly in the atherosclerotic rabbits (18) and the diabetic ApoE KO mice (46) , the endotheliumdependent relaxations to acetylcholine were preserved by a treatment with an antagonist of TP-receptor. Furthermore, in this latter model, a marked improvement of renal oxidant stress and proteinuria was observed following treatment with Triplion ® (41) . TP-receptors are present in renal tissues such as glomeruli and arteries (1, 21) and evidence for a role of vasoconstrictor eicosanoids in renal disease already exists for over a decade (27) . The activation of TP receptors is seldom associated with TXA 2 , but involves other activators such as isoprostanes or HETE's (3, 6, 46) . However, in human with diabetic nephropathy and in murine models of this pathology (12, 14) , TXA 2 itself has been implicated as a mediator of increased glomerular permeability to albumin (12) , although other TP-receptor agonists may contribute to the pathogenesis of diabetic kidney disease (41, 46) .
Murine models of atherosclerosis (ApoE KO and LDL receptor KO mice) and of diabetic atherosclerosis (diabetic ApoE KO mice) have been developed to evaluate atherogenesis and Page 4 of 48 its consequences on the vasculature. Antagonists of TP-receptors decrease atherosclerotic plaque formation in ApoE KO mice (6) and in diabetic ApoE KO mice (46) . This beneficial effect of TP receptor antagonists was mimicked by the deletion of the TP receptor gene in the mixed ApoE-TP-receptor KO mice (20) .
The purpose of the present work was to study the contribution of TP receptor in the vasoconstrictor and vasodilator mechanisms of the isolated and perfused murine kidney, and to determine whether or not early alterations in these mechanisms could be observed in the hypercholesterolemic ApoE KO mice and in the pre-atherosclerotic diabetic ApoE KO mice.
Methods

Isolated perfused mouse kidney.
Male ApoE-KO and their wild type counterparts (C57BL6) mice 7-15 weeks-old (body weight: 25.1 ዊ 0.2 g; n=113) were purchased from Charles River (Belgium), kept on regular diet and maintained in a humidity and temperature controlled room. All studies reported were performed in accordance with European Community Guidelines for the use of experimental animals and was approved by the ethical committee on Animal Experiments of the Servier Research Institute.
The experimental procedure was adapted from that used for the isolated perfused rat kidney (10) and afterwards used also in our laboratory (17, 34) . Mice were anaesthetized with sodium pentobarbitone (50 mg/kg, ip). The abdomen was opened by midline incision and the left renal artery was cannulated via an incision made in the aorta. Then the kidney was perfused at constant flow by a peristaltic pump (Gilson Minipuls), with a warmed (37°C) and oxygenated (95% O 2 -5% CO 2 ) Tyrode solution of the following composition (mM): NaCl 137; KCl 2.7; CaCl 2 1.8; MgCl 2 1.1; NaHCO 3 12.0; NaHPO 4 0.42; Ca-EDTA 0.026 and glucose 5.6. The perfused kidney was removed from the animal and placed in a perfusion chamber. The perfusate was not recirculated. Flow rate was adjusted to 0.9 ml/min (optimum flow rate) corresponding to 6 ml/min per g of kidney weight. The changes in renal vascular resistance were recorded as changes in perfusion pressure recorded downstream from the pump via a pressure transducer (P10 EZ, Statham, France) connected to a data acquisition system IOX (EMKA technologies, France). Once the perfusion pressure reached its steady state, after a 60-minute equilibration period, experiments were started. To add pharmacological agents to the perfusate two different sites were used: the substance was added via an infusion pump placed upstream from the perfusion pump or was injected as a bolus of 5 Nl into the perfusion Page 6 of 48 circuit, close to the kidney. The minimum time between successive doses of the agonists was 10 minutes. When necessary this interval was extended until the previous response had disappeared. In preliminary experiments, the perfused kidney and the non perfused contralateral kidney were weighted and were not found significantly different (138.7 ዊ 8.0 and 133.3 ዊ 9.8 mg, respectively, n = 6, P = NS), indicating the absence of edema formation.
Experimental protocols.
After equilibration, several bolus injections of norepinephrine (NE, 0.3 nmol) were performed to obtain a stable constrictor response that could serve as reference constriction for each kidney.
Part 1.
The first part of the study was performed to examine vasoconstrictor responses in the mouse kidney. Dose-response curves were constructed by injection of increasing doses of norepinephrine (NE; a non selective -adrenoceptor agonist, 10 pmol to 3 nmol), methoxamine (a selective 1 -adrenoceptor agonist, 10 pmol to 30 nmol), 5-hydroxytryptamine (5-HT, 10 pmol to 1 nmol), angiotensin II (Ang II, 0.1 pmol to 0.1 nmol), endothelin-1 (ET-1, 0.03 to 10 pmol), and the TP (Thromboxane A 2 /Prostaglandin H 2 )-receptor agonist U 46619 (1 to 30 pmol). The dose-response curves of the different agonists were performed at random in different series of mouse kidneys. Because of the difficulty to washout, the dose-response curve to ET-1 was always performed at the end of the protocol.
Since one of the goals of the study was to evaluate TP-receptor-induced renovascular responses, dose-response curves were also performed with a series of compounds, known to activate TP-receptors: arachidonic acid (AA; 10 pmol to 0.3 nmol), the endoperoxide PGH 2 (10 pmol to 3 nmol), the isoprostanes 8iso PGF 2 (0.1 to 10 nmol) and 8iso PGE 2 (10 pmol to 
Part 2.
The major goal of this part of the study was to verify the implication of TP-receptors in the renovascular responses to the vasoconstrictors. The selective TP-receptor antagonist, To verify the specificity of the ET-1-mediated constrictions, experiments were performed in the presence of the selective ET A and ET B antagonists, BQ-123 (1 NM) and BQ-788 (1 NM), respectively.
To verify the specificity of the response to AA, experiments were performed in the presence of the TXA 2 -synthase inhibitor dazoxiben (10 NM). In this series of experiments, the generation of thromboxane A 2 assay was quantified.
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Part 3.
Under the present experimental conditions, papaverine (10 nmol) did not affect basal perfusion pressure, indicating that the perfused murine kidney lacks intrinsic tone. Thus, to study vasodilator responses, a continuous renal vasoconstriction was produced by infusion of methoxamine (3 NM). During this response, vasodilator substances were injected as a bolus into the circuit with at least 10 minutes intervals.
Part 4.
In order to study the mechanisms involved in the mouse renal vasodilator responses, studies using inhibitors or antagonists were performed. Bolus injection of ACh, NO, PGI 2 , and ANP were performed during a methoxamine-induced vasoconstriction in the presence of Triplion® 
Pathological animals.
Two mouse models of cardiovascular disease were studied: the ApoE-KO mouse and the diabetic ApoE-KO mouse.
Diabetes induction.
Male ApoE-KO mice received a daily dose of Streptozotocin (Sigma-Aldrich, France) in 0.05M Na citrate pH 4.5 (70 mg/kg) for 5 days intraperitoneally at 7 weeks of age as described previously (46) . Diabetes was confirmed by measurement of non-fasting plasma glucose levels (tail stick) before the experiment. To be categorized as diabetic, the mice had to have non-fasting plasma glucose levels > 300 mg/dl. Three experimental groups of animals were then studied: C57Bl6 non-diabetic control mice, ApoE KO non-diabetic mice and diabetic ApoE KO mice. All animals were kept on a normal chow diet ad libitum, and diabetic mice were maintained without additional insulin injections. Height weeks later, the mice were used for the kidney perfusion experiments.
Biochemical measurements.
At the time of sacrifice, blood samples were collected from the heart in Li-heparin tubes. The plasma concentration of total and HDL cholesterol and triglycerides were determined using a colorimetric kit (ABX, France). 8iso PGF 2 plasma levels were assayed by ELISA (CaymanChemical, USA).
Vasoconstrictor agents.
To compare renal vascular constriction between the control mice, the ApoE KO mice and the diabetic ApoE KO mice, dose-response curves were performed in the isolated perfused kidney 
Vasodilator agents.
To study vasodilator responses, a sustained renal vasoconstriction was produced by infusion of methoxamine (3 NM) . During the vasoconstrictor responses the following vasodilator substances were injected: ACh (3 pmol to 0.3 nmol), NO (1 to 100 pmol), PGI 2 (10 nmol), ANP (10 pmol).
Expression of TP receptor in kidneys by quantitative real time-polymerase-chain reaction (PCR).
The right kidneys of ApoE KO and diabetic ApoE KO mice were harvested under pentobarbital anesthesia. Total RNA was extracted using RNeasy mini kit (Qiagen). Frozen kidneys were disrupted and homogenized in 300 Nl of RLT lysis buffer using a Mixer Mill 
Drugs.
Acetylcholine chloride, angiotensin II, rat atrial natriuretic peptide, arachidonic acid sodium, were performed in water.
The solution of NO was prepared as previously described (17) . Briefly glass bottles were filled with distilled water and were deoxygenated with N 2 . After preparation of a saturated solution of NO, adequate amounts of this solution were added with a syringe to the glass bottles, which were sealed. The stock solution was prepared intemperately. The final molar concentrations of the NO solutions were calculated on the basis that a saturated solution contains 4.6 % of NO.
Analysis of results.
Perfusion pressure was measured in mm Hg and changes in renal vascular pressure were expressed in delta mmHg versus basal perfusion pressure. Data are expressed as mean ዊ S.E.M.. The maximal response (Emax) and the pD 2 values which correspond to the negative logarithm of the dose of agonist which evoked 50% of the maximal response, were obtained from a non-linear sigmoid regression analysis for each dose-response curve (GraphPad PRISM, GraphPad Software, Inc., USA). n equals the number of animals from which the kidneys were taken.
Differences among the groups were determined by one-or two-way analysis of variance (ANOVA) followed by a Bonferroni test in the case of significant ANOVA. To evaluate significant differences between means before and after dazoxiben or Triplion ® , a Student's t test for paired or unpaired observations was performed. P < 0.05 was considered as statistically significant.
Results
Responses in kidneys of wild type mice.
Physiologic parameters.
The flow rate of 0.9 ml/min produced a constant pressure of 44.2 ዊ 1.5 mmHg (n=113)
corresponding to the basal perfusion pressure. The initial bolus injection of NE (0.3 nmol)
caused an increase in perfusion pressure that averaged 95.0 ዊ 5.2 mmHg (n=113).
Vasoconstrictor responses.
Bolus injections of increasing doses of various vasoconstricting agonists were production was significantly inhibited by dazoxiben (10 NM) (Fig. 2C ).
Dilator responses during tonic vasoconstrictions induced by methoxamine.
All the vasodilators tested did not modify perfusion pressure when added under basal conditions (i.e. without the presence of vasoconstrictors).
In the presence of the 1 -adrenergic agonist methoxamine (3 NM), ACh (3 pmol to 0.3 nmol) evoked biphasic responses; first a dose-dependent dilation followed by a second phase of dose-dependent constriction (Fig. 3A) while PGI 2 (10 nmol) first caused a vasoconstriction that was followed immediately by a vasodilatation (Fig. 4A ). Authentic NO (1 to 100 pmol), ANP (10 pmol) and papaverine (10 nmol) evoked only dilatations ( Table 2 ). control)
The dilator responses to ACh were not altered by indomethacin but were potentiated by Triplion ® (Fig. 3) . Both drugs inhibited the ACh-induced vasoconstrictions (Fig. 3 ).
Combined blockade of ET A and ET B receptors by BQ-123 and BQ-788 did not alter the AChinduced responses (data not shown).
The vasodilatations caused by PGI 2 were not modified by indomethacin or Triplion ® (Fig. 4) .
However, the PGI 2 -induced vasoconstrictions were enhanced by indomethacin and abolished by Triplion ® (Fig. 4) . BQ-123 + BQ-788 did not alter the PGI 2 -induced constriction (data not shown).
The vasodilator response to NO and papaverine were not modified by indomethacin (Table 2) or by BQ-123 + BQ-788 (data not shown) but they were potentiated by Triplion ® (Table 2) , whereas those to ANP were not altered by any of the treatments used (Table 2 ).
Pathological models.
The body weight, kidney weight, triglycerides as well as total and HDL cholesterol of ApoE KO mice were significantly higher than those of C57BL6 mice. Eight weeks after the induction of diabetes, blood glucose levels were markedly increased in diabetic mice. Their body weight was significantly lower than those of the two other strains whereas the ratio kidney weight -body weight was significantly higher. Total and HDL cholesterol were further augmented in diabetic ApoE KO mice but the ratio HDL versus total cholesterol
showed a large decrease of HDL cholesterol in non-diabetic (26%) or diabetic ApoE KO (16%) as compared to C57BL6 mice (69%). Finally, the plasma levels of 8iso PGF 2 were significantly higher in diabetic ApoE KO mice than in the two other groups (Table 3) .
The basal perfusion pressure of the perfused isolated kidney was similar between the groups: 36.8 ዊ 1.5 mmHg (n=36), 35 ዊ1.7 mmHg (n=33) and 34.1 ዊ 1.3 mmHg (n=37), respectively for C57BL6 and non-diabetic or diabetic ApoE KO mice.
Vasoconstrictor responses in non-diabetic or diabetic ApoE KO mouse kidneys. were not altered ( Fig. 5 and Table 4 ).
The concentration-response curve for the isoprostane, 8iso PGF 2 , was markedly shifted to the left in the-diabetic ApoE KO murine kidneys when compared to the other strains. To a lesser extent, the constrictions to U 46619 were also increased in the diabetic mice. At a concentration of 10 nM, the specific TP receptor antagonist, Triplion ® totally inhibited the constrictions evoked by U 46619 (0.1 nmol) and by 8iso PGF 2 (0.1 to 10 nmol), without altering those to NE (0.3 nmol) (144.4 ዊ 6.8 and 144.9 ዊ 7.4 mmHg (n=6), P=NS) (Fig. 6 ).
Vasodilator responses in non-diabetic or diabetic ApoE KO mouse kidneys. (Fig. 7) .
The biphasic responses to PGI 2 (10 nmol), the dose-dependent vasodilatations to authentic NO (1-100 pmol), as well as the vasodilatations to either ANP (10 pmol) or papaverine (10 nmol) were similar in the three different groups of mice (Table 5) .
TP receptor expression
Real-time RT-PCR detection (normalized to -actin, GAPDH and HPRT mRNA expression)
showed that the expression of the TP-receptor was not significantly altered in the kidney of diabetic ApoE KO mice (TP-receptor mRNA in arbitrary unit: 0.89 ± 0.26, n = 6 and 0.69 ± 0.15, n = 14, in ApoE KO and diabetic ApoE KO mice, respectively.).
Discussion
The present study shows that, in murine kidneys, the activation of TP-receptors is a potent vasoconstrictor stimulus, U 46619 exhibiting pD 2 and Emax values close to those of Ang II, and that the activation of this receptor impedes the response of various vasodilators such as ACh, PGI 2 and NO. Furthermore, in diabetic ApoE-KO mice an enhanced vasoconstriction to TP-receptor activation and especially in response to the isoprostane, 8iso-PGF 2 is observed.
The present work confirms that the isolated perfused mouse kidney is a convenient model to study vasoconstrictor and vasodilator responses (38, 39) . As reported for rat kidneys (10, 24, 35 ) the mouse renal vasculature is very sensitive to ET-1 and Ang II, and the reactivity to NE is comparable to that described for rat kidneys (10, 24) . However, the mouse renal circulation responds less to 5-HT but more potently to AA than rat kidneys (10, 25) .
The first objective of our study was to examine the possible involvement of TP- In murine kidneys, as reported in rat (17), PGI 2 caused also a biphasic response although, in contrast to ACh, the constriction is observed first and is followed by a sustained Therefore, this study shows that the murine isolated and perfused kidney is a reliable model that shares some characteristics with the rat perfused kidney. In murine kidneys, the activation of TP-receptors is a potent vasoconstrictor stimulus that reduces response of various vasodilators such as ACh, PGI 2 and NO.
Mouse models of atherosclerosis and diabetes may help to understand renal dysfunction related to early disease stages. In these models, the protective effects of TPreceptor antagonism on development of atherosclerosis were recently demonstrated (6, 41, 46) . The hypercholesterolemic ApoE KO mouse presents early atherosclerotic lesions comparable to human lesions (44) and they can be accelerated by hyperglycemia (41, 46) .
Non-diabetic apoE KO mice do not have normal glomeruli, but often have lipid deposits and a mild degree of glomerulosclerosis. The apoE KO is a specific atherosclerosis prone mouse model with increased remnant lipoproteins. It is expected that these mice show some vascular abnormalities, further accelerated in the context of diabetes. In our models the relatively short duration of hypercholesterolemia and diabetes produces only minor but visible alterations in the kidney tubular morphology without evidence of atherosclerosis (data not shown).
Mesangial expansion is a key feature in the pathogenesis of numerous renal diseases, including diabetic nephropathy, involving the glomerulus. In apoE-null mice a lipidindependent effects on mesangial expansion has been described (8 (11) . In the mesenteric artery of Apo-E KO mice, the response to ACh is not altered (13) while in that of the streptozotocin-treated Apo-E KO mice an overall decrease response is attributed to a decrease EDHF component, and an increase EDCF component with a paradoxical increase compensatory NO component (13, 22) .
In the carotid artery of Apo-E KO mice fed with a Western-type diet, the ACh-induced relaxations are apparently unaltered but a decrease in the NO component is compensated by the endothelial production of vasodilator prostaglandins (16) . The transient vasoconstrictions induced by ACh are decreased in the diabetic animals while those to exogenously added prostacyclin are maintained. This suggests that the generation by ACh of a putative EDCF is diminished. To dissect the various mechanisms underlying the vasodilator response of the murine kidneys was beyond the scope of the present study. This matter must be specifically addressed in further work.
Nevertheless, without obvious changes in vasodilator responses, changes in responses to vasoconstrictors were observed in ApoE KO and diabetic ApoE KO mice. In ApoE KO mice, constrictions to NE are decreased, which was also observed in arteries of hypercholesterolemic rabbits, early during atherosclerosis (33). An intriguing observation is that NE-constrictions are increased in diabetic animals, suggesting that diabetes, but not atherosclerosis, causes augmented constrictor activity to NE. Nevertheless, the most profound change is associated with TP-receptor activation in the diabetic animals. In diabetic mice the responses to the TP-receptor agonist U 46619 were slightly augmented and those to the isoprostane 8iso PGF 2 were very significantly increased. The increased vasoconstrictor response to these agonists in the diabetic mice is unlikely to be attributed to an increase expression of the TP-receptor in the kidney since mRNA expression was not altered. The diabetic ApoE mice have increase levels of circulating 8iso PGF 2 , indicating an increase oxidative stress in these animals (23) . Oxidative stress can potentiate the response to TPreceptor activation by changes in post receptor transducing signal (9) or following changes at the TP-receptor itself. For instance, oxidative stress stabilizes the TP-receptor (32) and heterodimerization of the and isoforms of the TP-receptor enhances isoprostane signaling (39) . Isoprostanes are not simply biomarkers for oxydative stress, they activate TP-receptors and their elevated levels along with an exaggerated TP-receptor signaling can contribute to renal malfunctioning in diabetes.
The diabetic apoE KO have significantly higher total cholesterol levels compared to the non-diabetic apoE KO. It is difficult to determine if the observed changes are mediated by the increase in lipids or by the diabetic milieu per se. By using a non-chemical method to produce a mouse model of insulin-deficient diabetes, Renard et al. showed that this model is associated with larger vascular lesions in mice on chow diets and suggests that diabetes increases lesion initiation and is associated with development of advanced lesions (28).
Elevated glucose in diabetes has been recognized to increase levels of arachidonic acid metabolites, likely as a result of the increased vascular inflammation. In aging ApoE KO mice, isoprostanes levels are increased suggesting an age-dependent increase in lipid peroxidation products (26). In each case, both diabetes and/or hyperlipidemia are responsible for the increased oxidative stress and their association is responsible for the alterations that produce the dramatic acceleration of renal disease in diabetic ApoE KO mice (41).
In conclusion, in ApoE KO and diabetic ApoE KO mice, normal vasodilator responses, but altered constrictor responses are observed and the latter involves TP-receptor activation. This suggests that in the very early stages of atherosclerotic and/or diabetic atherosclerotic disease, an enhanced TP-receptor activation is an early marker of renal dysfunction and this pathway is a possible contributor in the exacerbation of the disease. Values are shown as means ± S.E.M.; n equals the number of animals used. nd: not determined. a increase in perfusion pressure at the highest dose of 8iso PGF 2 used (10 nmol).
The pD 2 value for 8iso PGF 2 was not calculated because maximal constriction was not obtained. 
Control
Non-diabetic ApoE Diabetic ApoE Norepinephrine 9.46 ± 0.07 (7) 9.30 ± 0.06 (7) 9.55 ± 0.13 (8)
U 46619
10.64 ± 0.12 (7) 10.48 ± 0.14 (8) 10.90 ± 0.15 (8) 5-HT 9.31 ± 0.31 (7) 9.18 ± 0.28 (7) 9.18 ± 0.39 (9) 8iso PGF 2 nc (9) nc (8) 8.48 ± 0.20 (9) ET-1 11.80 ± 0.14 (5) 11.83 ± 0.16 (5) 12.08 ± 0.12 (5)
Ang II
11.86 ± 0.12 (5) 11.78 ± 0.14 (5) 11.93 ± 0.16 (5) Data are expressed as means ዊ S.E.M. The number of animals is indicated between brackets.
The pD 2 value for 8iso PGF 2 was not calculated because maximal constriction was not obtained. nc: not calculated 
